The clinical performance of NIS2+TM was superior to that of NIS4®, FIB-4, NFS, ALT, and ELFTM for the identification of at-risk NASH in patients aged ≥65 years. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.